Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer
JAMA · 25.06.2024 · 331 (24) · 2084
DOI: 10.1001/jama.2024.6695 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, erschienen am 25.06.2024. Verfasst von Lisa F Newcomb und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington. Hauptthemen laut MEDLINE: Clinical Protocols, Prostate-Specific Antigen, Prostatic Neoplasms, Watchful Waiting. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Outcomes from protocol-directed active surveillance for favorable-risk prostate cancers are needed to support decision-making.
Objective
To characterize the long-term oncological outcomes of patients receiving active surveillance in a multicenter, protocol-directed cohort. Design, Setting, and Participants The Canary Prostate Active Surveillance Study (PASS) is a prospective cohort study initiated in 2008. A cohort of 2155 men with favorable-risk prostate cancer and no prior treatment were enrolled at 10 North American centers through August 2022. Exposure Active surveillance for prostate cancer. Main Outcomes and Measures Cumulative incidence of biopsy grade reclassification, treatment, metastasis, prostate cancer mortality, overall mortality, and recurrence after treatment in patients treated after the first or subsequent surveillance biopsies.
Results
Among 2155 patients with localized prostate cancer, the median follow-up was 7.2 years, median age was 63 years, 83% were White, 7% were Black, 90% were diagnosed with grade group 1 cancer, and median prostate-specific antigen (PSA) was 5.2 ng/mL. Ten years after diagnosis, the incidence of biopsy grade reclassification and treatment were 43% (95% CI, 40%-45%) and 49% (95% CI, 47%-52%), respectively. There were 425 and 396 patients treated after confirmatory or subsequent surveillance biopsies (median of 1.5 and 4.6 years after diagnosis, respectively) and the 5-year rates of recurrence were 11% (95% CI, 7%-15%) and 8% (95% CI, 5%-11%), respectively. Progression to metastatic cancer occurred in 21 participants and there were 3 prostate cancer–related deaths. The estimated rates of metastasis or prostate cancer–specific mortality at 10 years after diagnosis were 1.4% (95% CI, 0.7%-2%) and 0.1% (95% CI, 0%-0.4%), respectively; overall mortality in the same time period was 5.1% (95% CI, 3.8%-6.4%). Conclusions and Relevance In this study, 10 years after diagnosis, 49% of men remained free of progression or treatment, less than 2% developed metastatic disease, and less than 1% died of their disease. Later progression and treatment during surveillance were not associated with worse outcomes. These results demonstrate active surveillance as an effective management strategy for patients diagnosed with favorable-risk prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
- Department of Urology, University of Washington, Seattle.
- Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
- Department of Urology, Stanford University, Stanford, California.
- Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.
- Department of Urology, Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
Förderung
- NCI NIH HHS
Zitieren
APA
Newcomb, L. F., Schenk, J. M., Zheng, Y., Liu, M., Zhu, K., Brooks, J. D., Carroll, P. R., Dash, A., de la Calle, C. M., Ellis, W. J., Filson, C. P., Gleave, M. E., Liss, M. A., Martin, F., McKenney, J. K., Morgan, T. M., Tretiakova, M. S., Wagner, A. A., Nelson, P. S., & Lin, D. W. (2024). Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer. JAMA, 331(24), 2084. https://doi.org/10.1001/jama.2024.6695
Vancouver
Newcomb LF, Schenk JM, Zheng Y, Liu M, Zhu K, Brooks JD, et al. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer. JAMA. 2024;331(24):2084. doi:10.1001/jama.2024.6695
BibTeX
@article{Newcomb2024,
author = {Newcomb, Lisa F and Schenk, Jeannette M and Zheng, Yingye and Liu, Menghan and Zhu, Kehao and Brooks, James D and Carroll, Peter R and Dash, Atreya and de la Calle, Claire M and Ellis, William J and Filson, Christopher P and Gleave, Martin E and Liss, Michael A and Martin, Frances and McKenney, Jesse K and Morgan, Todd M and Tretiakova, Maria S and Wagner, Andrew A and Nelson, Peter S and Lin, Daniel W},
title = {Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer},
journal = {JAMA},
year = {2024},
volume = {331},
number = {24},
pages = {2084},
doi = {10.1001/jama.2024.6695}
}
EUVIMED